Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study

Table 3 Characteristics of 56 patients with BRAF V600E-mutated mCRC in standard therapy group (treated with cytotoxic doublets with or without bevacizumab regimen) and intensive therapy group (treated with modified FOLFOXIRI regimen)

Variable	Standard therapy group (n = 50)	Intensive therapy group (n = 6)
Gender
Male	16 (32.0)	4 (66.7)
Female	34 (68.0)	2 (33.3)
ECOG performance status
0	42 (84.0)	5 (83.3)
1	8 (16.0)	1 (16.7)
2	0 (0)	0 (0)
Primary tumor
Right	23 (46.0)	4 (66.7)
Left	15 (30.0)	2 (33.3)
Rectum	12 (24.0)	0 (0)
No. of involved organs
1	13 (26.0)	4 (66.7)
> 1	37 (74.0)	2 (33.3)
Liver metastases
Yes	23 (46.0)	6 (100)
No	27 (54.0)	0 (0)
Peritoneal metastases
Yes	18 (36.0)	1 (16.7)
No	32 (64.0)	5 (83.3)
Distant lymph node metastasis
Yes	38 (76.0)	5 (83.3)
No	12 (24.0)	1 (16.7)
Lung metastasis
Yes	9 (18.0)	0 (0)
No	41 (82.0)	6 (100)
Mucinous or signet-ring cell components
Yes	9 (18.0)	1 (16.7)
No	41 (42.0)	5 (83.3)
Differentiation (adenocarcinoma)^a
Well-moderate	27 (54.0)	4 (66.7)
Poor	20 (40.0)	2 (33.3)

All values are presented as number of patients followed by percentage in parentheses
FOLFOXIRI 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan
^aThree cases were pure signet-ring cell carcinomas or mucinous carcinomas and were excluded here

ISSN: 2523-3548